Financials

News Discussions Technicals Seasonals

XINT fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Xintela AB is a biomedical company. It engages in the business of developing medical products in stem cell therapy and targeted cancer therapy based on the cell surface marker integrin a10ß1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The company was founded by Evy Lundgren-Åkerlund and Rickard Mosell in 2009 and is headquartered in Lund, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

XINT has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company